Discontinued — last reported Q2 '23
Halliburton Acquisitions increased by 870.0% to $97.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.4%, from $116.00M to $97.00M. Over 2 years (FY 2023 to FY 2025), Acquisitions shows an upward trend with a 277.2% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.25M | $3.25M | $3.25M | $3.25M | $0.00 | $22.00M | $5.00M | $0.00 | $116.00M | $46.00M | $13.00M | $10.00M | $97.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | -77.3% | -100.0% | — | -60.3% | -71.7% | -23.1% | +870.0% |
| YoY Change | — | — | — | — | -100.0% | +576.9% | +53.8% | -100.0% | — | +109.1% | +160.0% | — | -16.4% |